Replacing the Needle and Syringe with a Patch to Deliver Vaccines with Michael Schrader Vaxess TRANSCRIPT
Download PDFJul 31, 2022
Michael Schrader is CEO and Co-Founder of Vaxess Technologies, which is transforming vaccine delivery from needles and syringes to a skin patch delivery system. Their solution reduces the need to have mass vaccination sites, makes vaccines easier and cheaper to transport, and addresses the reluctance of patients to get...
Jul 30, 2022
Michael Schrader is CEO and Co-Founder of Vaxess Technologies, which is transforming vaccine delivery from needles and syringes to a skin patch delivery system. Their solution reduces the need to have mass vaccination sites, makes vaccines easier and cheaper to transport, and addresses the reluctance of patients to get...
Enhancing Response to Checkpoint Inhibitor Therapy Using Presence of Telomerase Enzyme to Direct Cancer Vaccine with Dr. Jens Bjørheim Ultimovacs TRANSCRIPT
Download PDFApr 4, 2022
Dr. Jens Bjørheim is the Chief Medical Officer at Ultimovacs which is taking advantage of the environment for R&D in the science around cancer vaccines in the Oslo region of Norway. Ultimovacs is working with peptide vaccines and long peptides. These peptides will drive for a specific subgroup of immune cells called...
Apr 4, 2022
Dr. Jens Bjørheim is the Chief Medical Officer at Ultimovacs which is taking advantage of the environment for R&D in the science around cancer vaccines in the Oslo region of Norway. Ultimovacs is working with peptide vaccines and long peptides. These peptides will drive for a specific subgroup of immune cells called...
Treating Cancers and Infectious Diseases by Engaging the Lymph Nodes with Bob Connelly Elicio Therapeutics TRANSCRIPT
Download PDFDec 2, 2021
Bob Connelly is the CEO of Elicio Therapeutics which has figured out how to deliver immunotherapies from vaccines into the lymph nodes where they are activated to defeat cancer and infectious diseases.
Bob says, "Our overall mission is to treat many different types of cancers primarily, but even to bring our technology...